IBio And Planet Biotech Reach License Agreement For Development Of COVID-19 Therapeutic

(RTTNews) - Shares of iBio Inc. (IBIO) were gaining 14 percent in pre-market trading on Friday, after the company said it has reached an exclusive worldwide license agreement with Planet Biotechnology for the development of Planet's COVID-19 therapeutic candidate, ACE2-Fc.

As per the terms of the deal, iBio obtained an exclusive license to Planet's ACE2-Fc. Planet is eligible to receive certain pre-specified payments upon achievement of clinical development milestones.

In the pre-market trading, IBIO was trading at $2.42 up $0.31 or 14.69 percent.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.